drugset / Trial / NCT01531244

Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma

NCT01531244

NaSingle-groupOpen-labelTreatment

Summary

This phase I/II trial studies the safety, best dose and effectiveness of targeted gene therapy combined with isolated limb infusion (ILI) of melphalan and dactinomycin for treating patients with advanced extremity melanoma that cannot be removed by surgery. Adding gene therapy to a standard chemotherapy regimen in the isolated limb may enhance anti-cancer effects by inducing a systemic immune response against the tumor cells.

Timeline

Start
2014-12
Primary completion
2016-02
Completion
2016-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Conditionally replicative adenovirus 3/5-delta Unknown Other
Background Dactinomycin Protein / enzyme biologic Other
Background Melphalan Small molecule Other

Indications